Quick answer: PT-141, also called bremelanotide, is one of the few peptides discussed across this whole space that actually has full FDA approval. It was approved in 2019, under the brand name Vyleesi, for treating low sexual desire in premenopausal women. It works differently than most other sexual health drugs. Instead of acting on blood flow like some other treatments, it acts on receptors in the brain tied to desire and arousal.
Where PT-141 Came From
PT-141's story starts with a completely different peptide, Melanotan II, which was originally studied as a tanning agent. During early research on Melanotan II, scientists noticed something they were not looking for. Some of the people in the studies reported changes in sexual arousal, not just changes in skin tone.
That unexpected finding shifted the research. Scientists took Melanotan II and modified it, removing parts of the molecule tied to skin pigment changes while keeping the parts tied to sexual arousal. The result was a new, smaller peptide called bremelanotide, which became PT-141.
How PT-141 Actually Works
Most well known treatments for sexual dysfunction, like the ones used for erectile dysfunction, work by increasing blood flow to a specific area of the body. PT-141 works completely differently. It activates receptors in the brain and central nervous system, mainly two called MC3R and MC4R, that are tied to desire and arousal signals.
Because it works in the brain rather than on blood flow, PT-141 is studied for low desire and arousal issues rather than the more mechanical problems that blood flow focused drugs are built for.
What Makes This Peptide Different From Most Others on This Site
Nearly every other peptide covered on this site is labeled research use only, meaning it has not completed the FDA approval process. PT-141 is a real exception. As bremelanotide, it went through large, multi phase human clinical trials involving thousands of participants and received FDA approval in 2019 for treating hypoactive sexual desire disorder in premenopausal women, a condition defined as low sexual desire that causes real personal distress.
This matters for how you think about the two names. Bremelanotide, sold as Vyleesi, is the approved prescription drug, given through an auto injector under a doctor's care. PT-141 sold through research peptide channels is the same molecule, but sold outside that approved, prescription pathway, which puts it back into research use only territory the same as everything else discussed on this site.
Did It Cause the Tanning Effect Like Melanotan II?
This was a real concern during PT-141's development, since it came from a tanning peptide. Researchers specifically checked for this in the clinical trials, using photography and skin measurement tools, and did not find meaningful skin darkening or new moles in people using bremelanotide compared to a placebo group. This is thought to come down to PT-141 being far less active at the specific receptor tied to skin pigment, plus how infrequently it is dosed compared to Melanotan II.
Myth vs. Fact
Myth: PT-141 and Melanotan II are basically the same thing. Fact: They are related, since PT-141 was developed from Melanotan II research, but they act on different receptors with different effects. PT-141 was specifically built to reduce the pigment changing effects that Melanotan II is known for.
Myth: Since it is FDA approved as Vyleesi, any PT-141 you find online carries the same safety guarantee. Fact: The approval applies to Vyleesi specifically, the prescription product made under strict pharmaceutical manufacturing standards. PT-141 sold through research channels is not manufactured or regulated the same way, even though it is the same molecule.
Bottom Line
PT-141 stands out in this space because it is one of the rare peptides with a real, completed human trial program and full FDA approval behind it, under the name Vyleesi. That approval applies to the regulated pharmaceutical product specifically, not to every version of the peptide sold under the research use only label.
Research use only, unless obtained as the prescription product Vyleesi through a licensed provider. This article is for general education and is not medical advice. Talk to a licensed doctor about any sexual health concern.
Sources referenced: FDA approval records for bremelanotide (Vyleesi), 2019; clinical trial data on PT-141 skin pigmentation assessments; mechanism research on melanocortin receptors and hypoactive sexual desire disorder.